Occult Tumor Cell Contamination in Patients With Stage II/III Breast Cancer Receiving Sequential High-Dose Chemotherapy

Bone Marrow Transplantation - United Kingdom
doi 10.1038/sj.bmt.1704283
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Test of a Weight Gain Prevention Intervention in Stage II and III Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

Cancer Epidemiology Biomarkers and Prevention
MedicineEpidemiologyOncology
2010English

2-Year Single Center Clinical Experience in Patients With Colon Cancer Stage II and III Receiving Adjuvant Chemotherapy

Scripta Scientifica Medica
2015English

Leptotrichia Bacteremia in Patients Receiving High-Dose Chemotherapy

Journal of Clinical Microbiology
Microbiology
2011English

Quantitative Ultrasound Evaluation of Tumor Cell Death Response in Locally Advanced Breast Cancer Patients Receiving Chemotherapy

Clinical Cancer Research
Cancer ResearchOncology
2013English

High-Dose Chemotherapy in High-Risk Breast Cancer

Breast Cancer Research
Cancer ResearchOncology
2000English

Is High-Dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplantation in Breast Cancer Patients a Done Deal?

Women's Health
Medicine
2010English

Stability of Symptom Clusters in Patients With Breast Cancer Receiving Chemotherapy

Journal of Pain and Symptom Management
NeurologyAnesthesiologyPain MedicineNursing
2018English

Long-Term Prognostic and Predictive Factors in 107 Stage II/III Breast Cancer Patients Treated With Anthracycline-Based Neoadjuvant Chemotherapy

British Journal of Cancer
Cancer ResearchOncology
1997English

High-Dose Chemotherapy (CTM) for Breast Cancer

Bone Marrow Transplantation
TransplantationHematology
2000English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy